

Scholar Rock Holding Corporation, a biopharmaceutical company, focuses on the discovery and development of medicines for the treatment of serious diseases in which signaling by protein growth factors plays a fundamental role. The company develops Apitegromab, an inhibitor of the activation of latent myostatin that has completed the Phase 3 clinical trials for the treatment of spinal muscular atrop⦠read more
Healthcare
Biotechnology
7 years
USD
Exclusive to Premium users
$49.78
Price+1.21%
$0.59
$5.966b
Mid
-
Premium
Premium
-
EBITDA Margin-
Net Profit Margin-
Free Cash Flow Margin-
EBITDA Margin-
Net Profit Margin-
Free Cash Flow Margin$0.00
-
1y CAGR-
3y CAGR-25.0%
5y CAGR-$408.726m
-8.1%
1y CAGR-36.7%
3y CAGR-33.4%
5y CAGR-$3.45
-4.9%
1y CAGR-20.7%
3y CAGR-13.1%
5y CAGR$276.013m
$535.254m
Assets$259.241m
Liabilities$205.674m
Debt38.4%
-0.5x
Debt to EBITDA-$303.860m
-1.1%
1y CAGR-29.7%
3y CAGR-24.4%
5y CAGR